News Releases
- June 9, 2022Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
- December 14, 2021Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
- November 15, 2021Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
- November 12, 2021Annovis Bio Presented at the 14th Clinical Trials on Alzheimer’s Disease Conference
- November 9, 2021Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- November 2, 2021Annovis Bio to Present at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- October 5, 2021Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease
- September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference
- September 10, 2021Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- September 3, 2021Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report®
- May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
- April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
- April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - December 2023
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top